Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

By Prosper Junior Bakiny – Feb 20, 2026 at 12:30PM ESTKey PointsCRISPR Therapeutics has some promising and innovative pipeline candidates.The stock will soar if it can execute and deliver strong clinical and regulatory progress. We’re bullish on these 10 stocks ›NASDAQ: CRSPCRISPR TherapeuticsMarket Cap$5.2BToday's Changeangle-down(-1.34%) $0.73Current Price$53.91Price as of February 20, 2026 at 1:48 PM ETThe past few years have been challenging for the biotech.CRISPR Therapeutics (CRSP 1.34%) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first gene-editing therapy to use the famous, Nobel Prize-winning CRISPR gene-editing system to earn approval. CRISPR Therapeutics has lagged the market since that breakthrough, but with some highly promising gene-editing medicines in its pipeline and potential upcoming catalysts, some investors are excited about the biotech's future. Can CRISPR Therapeutics live up to the hype, or will it be a wealth destroyer from here on out? Image source: Getty Images. Several breakthroughs in the making CRISPR Therapeutics' gene-editing approach could revolutionize standards of care in areas with high unmet needs. That's one of the best reasons to consider the stock. The company's pipeline includes several promising medicines for which we should see progress over the next 12 to 18 months. If the data is positive, CRISPR Therapeutics' shares will jump. Consider the company's zugo-cel, a potential treatment for a range of cancers and autoimmune diseases. It belongs to a group of medicines known as CAR-T therapies, which are engineered from healthy T-cells. The problem is, many are made from patients' own cells, which severely limits their manufacturing capacity. They also come with potential drawbacks and side effects, including immune rejection. Zugo-cel is being developed to bypass these issues. It is made from healthy donor cells (not the patients'), which makes manufacturing easier, while it aims to reduce the risk of immune rejection (and other problems) through the gene-editing approach. ExpandNASDAQ: CRSPCRISPR TherapeuticsToday's Change(-1.34%) $-0.73Current Price$53.91Key Data PointsMarket Cap$5.2BDay's Range$52.94 - $55.0052wk Range$30.04 - $78.48Volume27KAvg Vol1.8MGross Margin-653467.24% Zugo-cel has received the Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (FDA), which aims to help speed the development and approval of certain types of treatments (including gene-editing therapies) that have shown promising early clinical evidence for serious diseases with high unmet needs. CRISPR Therapeutics' pipeline also includes CTX310, a treatment that could advance how we help patients lower bad cholesterol, and SRSD107, a promising next-gen anticoagulant. Beware of the risks CRISPR Therapeutics' platform looks very promising, but the company's performance will depend on whether it can execute its clinical programs while limiting setbacks. If CRISPR Therapeutics' leading candidates flunk in clinical trials, the company's shares will soar. So, although the hype isn't unjustified -- the biotech's candidates could change the way we treat several conditions -- there is also plenty of risk. My view is that even if some current candidates fail, others will succeed. And CRISPR Therapeutics is more likely to get acquired than to go to $0. So, investors comfortable with a healthy dose of volatility should consider the stock.Read NextFeb 20, 2026 •By James HalleyThe Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These PricesFeb 19, 2026 •By Adria Cimino2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall StreetFeb 18, 2026 •By Justin PopeShould You Buy Shares of CRISPR Therapeutics in February?Feb 13, 2026 •By Adria CiminoThe Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026Feb 13, 2026 •By James BrumleyWhy CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)Jan 29, 2026 •By Prosper Junior BakinyForget AI Stocks: This Biotech Could Cure What AI Can't TouchAbout the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedCRISPR TherapeuticsNASDAQ: CRSP$53.91 (1.34%) $0.73*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.